Diligence memo · auto-generated · as of July 2, 2026
NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
NovaBay Pharmaceuticals, Inc. operates in Pharmaceuticals, based in EMERYVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NovaBay Pharmaceuticals, Inc. has raised $218M in disclosed capital across 16 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $134M on 2026-01-16.
Most recent recorded round closed around 2026-01-16.
Valuation (modeled)modeled
Provath models NovaBay Pharmaceuticals, Inc. at approximately $913M (range $638M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Series D+ Pharmaceuticals companies in 2025–2027 (7 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 5 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 593.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: DBV Technologies S.A., Galecto, Inc., Pelage Pharmaceuticals, Inc., Triana Biomedicines, Inc., Quoin Pharmaceuticals, Ltd..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.